Moreover, a branched sialylated glycan was recently found to act as a ligand of Siglec-3 (CD33), which is believed to be involved in the pathogenesis of late-onset AD [204], expanding the scope of possibilities for therapeutic interventions in AD. The gene discussed is CD33; the disease is Alzheimer disease.